AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
KEEGO HARBOR, Mich., March 22, 2017 -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, announces that a new corporate website featuring the latest project news and investor information is up and running at http://www.zivobioscience.com/ and updates are planned to appear on a regular, monthly basis.
Several weeks earlier, the Company had mailed announcements to current ZIVO shareholders advising them of an email contact program that would deliver timely Company news to a subscribers’ email inbox. Both the revamped website and email contact program are part of a renewed effort by management to advise shareholders and other interested parties of significant developments in the Company’s R&D and compliance activities, strategic partnering, as well as the marketing of intellectual property.
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. (OTC:ZIVO.QB) is a Michigan-based biotech company engaged in the investigation of the health benefits of nutritive components derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
Contact: Investor Relations (248) 452 9866 ext 150 ZIVO Bioscience, Inc. [email protected]
